<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053792</url>
  </required_header>
  <id_info>
    <org_study_id>CSL654_3003</org_study_id>
    <secondary_id>2012-005489-37</secondary_id>
    <nct_id>NCT02053792</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B</brief_title>
  <official_title>A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <brief_summary>
    <textblock>
      This study will examine the long-term safety and efficacy of rIX-FP for the control and&#xD;
      prevention of bleeding episodes in children and adults with severe hemophilia B. The study&#xD;
      will include subjects who have not previously been treated with Factor IX products, subjects&#xD;
      who previously completed a CSL-sponsored rIX-FP lead-in study and subjects requiring major&#xD;
      non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study.&#xD;
&#xD;
      A surgical prophylaxis substudy will examine the efficacy of rIX-FP in subjects with&#xD;
      hemophilia B who are undergoing non-emergency major or minor surgery. An additional substudy&#xD;
      will examine the safety and PK of subcutaneous (SC) administration of rIX-FP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2014</start_date>
  <completion_date type="Actual">June 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 2, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total number of subjects who develop inhibitors against factor IX (FIX)</measure>
    <time_frame>Approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental recovery in previously untreated patients (PUPs)</measure>
    <time_frame>Approximately 30 minutes after infusion</time_frame>
    <description>Incremental recovery expressed as IU/dL per IU/kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of annualized bleeding rate between different prophylaxis treatment intervals.</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Comparison of annualized bleeding rate by prophylaxis treatment interval for spontaneous treated bleeds and total treated bleeds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of annualized bleeding rate between 2 different prophylaxis treatment intervals and on-demand treatment.</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>For subjects from the lead-in study (CSL654_3001 [NCT01496274]), comparison of the annualized bleeding rate of spontaneous treated bleeds and total treated bleeds between routine prophylaxis treatment in this study (CSL654_3003) and:&#xD;
On-demand treatment during the lead-in study (CSL654_3001).&#xD;
Routine prophylaxis treatment with the different treatment interval used by the subject in the lead-in study (CSL654_3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rIX-FP consumed per month per subject during routine prophylaxis treatment.</measure>
    <time_frame>Approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall adverse events (AEs) and rIX-FP-related AEs</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>The overall percentage of subjects with at least one AE, and the overall percentage of subjects with at least one rIX-FP-related AE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic response to rIX-FP treatment in PUPs</measure>
    <time_frame>Hemostatic response of rIX-FP treatment during the course of the study (up to 5 years)</time_frame>
    <description>The investigator will rate the efficacy of the rIX-FP treatment based on a hemostatic efficacy four point rating scale of &quot;excellent, good, moderate or poor/no response&quot;.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>rIX-FP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years.&#xD;
The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP.&#xD;
For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter.&#xD;
The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rIX-FP</intervention_name>
    <description>Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)</description>
    <arm_group_label>rIX-FP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Main study inclusion criteria:&#xD;
&#xD;
        For previously treated subjects, either:&#xD;
&#xD;
          -  Completed a CSL-sponsored rIX-FP (CSL654) study, including study CSL654_3001&#xD;
             [NCT01496274] or study CSL654_3002 [NCT01662531].&#xD;
&#xD;
        Or:&#xD;
&#xD;
          -  Scheduled to have a major non-emergency surgery within approximately 8 weeks from the&#xD;
             anticipated date of receiving the first rIX-FP injection.&#xD;
&#xD;
          -  Not previously completed a CSL-sponsored rIX-FP lead-in study.&#xD;
&#xD;
          -  Male, 12 to 70 years of age.&#xD;
&#xD;
          -  Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by&#xD;
             the central laboratory.&#xD;
&#xD;
          -  Subjects who have received FIX products (plasma-derived and / or recombinant FIX) for&#xD;
             &gt; 150 exposure days (EDs), confirmed by their treating physician.&#xD;
&#xD;
          -  No confirmed history of FIX inhibitor formation at screening by the central laboratory&#xD;
&#xD;
        For previously untreated subjects:&#xD;
&#xD;
          -  Male, up to 18 years of age.&#xD;
&#xD;
          -  Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by&#xD;
             the central laboratory.&#xD;
&#xD;
          -  Never previously been treated with FIX clotting factor products (except previous&#xD;
             exposure to blood components).&#xD;
&#xD;
          -  No confirmed history of FIX inhibitor formation&#xD;
&#xD;
        Surgery substudy inclusion criterion:&#xD;
&#xD;
          -  Must require non-emergency surgery&#xD;
&#xD;
        Subcutaneous substudy inclusion criteria:&#xD;
&#xD;
          -  Male, at least 18 years of age.&#xD;
&#xD;
          -  Subjects currently enrolled in Study CSL654_3003&#xD;
&#xD;
          -  Subjects who have received rIX-FP for ≥ 100 EDs (single-dose cohorts) or for ≥ 50 EDs&#xD;
             (repeated-dose cohort)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Main study exclusion criteria:&#xD;
&#xD;
          -  Currently receiving a therapy not permitted during the study.&#xD;
&#xD;
          -  Any issue that, in the opinion of the investigator, would render the subject&#xD;
             unsuitable for participation in the study.&#xD;
&#xD;
        For subjects who have previously completed a CSL-sponsored rIX-FP study:&#xD;
&#xD;
          -  Unwilling to participate in the study for a total of 100 exposure days.&#xD;
&#xD;
        For subjects requiring major non-emergency surgery who have not previously completed a&#xD;
        CSL-sponsored rIX-FP lead-in study:&#xD;
&#xD;
          -  Known hypersensitivity (ie, allergic reaction or anaphylaxis) to any FIX product or&#xD;
             hamster protein.&#xD;
&#xD;
          -  Known congenital or acquired coagulation disorder other than congenital FIX&#xD;
             deficiency.&#xD;
&#xD;
          -  Currently receiving IV immunomodulating agents such as immunoglobulin or chronic&#xD;
             systemic corticosteroid treatment.&#xD;
&#xD;
          -  Low platelet count, kidney or liver disease.&#xD;
&#xD;
          -  Human immunodeficiency virus positive with a CD4 count &lt; 200/mm3.&#xD;
&#xD;
        For previously untreated subjects:&#xD;
&#xD;
          -  Known congenital or acquired coagulation disorder other than congenital FIX deficiency&#xD;
             (except for vitamin K deficiency of the newborn).&#xD;
&#xD;
          -  Known kidney or liver dysfunction or any condition which, in the investigator's&#xD;
             opinion, place the patient at unjustifiable risk.&#xD;
&#xD;
        The surgical substudy does not have any additional exclusion criteria, although subject(s)&#xD;
        in France will not be eligible for the surgery sub-study.&#xD;
&#xD;
        Subcutaneous substudy exclusion criteria:&#xD;
&#xD;
          -  Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP.&#xD;
&#xD;
          -  Life-threatening bleeding episode or major surgery during the 3 months prior to&#xD;
             substudy entry&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Westmead</name>
      <address>
        <city>Westmead</city>
        <state>Victoria</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Vienna General Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT &quot;Joan Pavel&quot; ODD [Hemorrhagic Diathesis &amp; Anemia]</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocrice Ostrava</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Bicetre - Centre de Traitement del'Hemophilia</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfants La Timonepital</name>
      <address>
        <city>Marseille Cedex</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur experimentelle Hamatologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Hess Kinderklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRC Coagulation Research Centre GmbH</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich Heine University Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universtatsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Werlhof-Institute for Haemostasis and Thrombosis</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurpfalzkrankenhaus Heidlerberg GmbH</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore[Centro emofilia e Trobosi]</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOS Gestione e Organizzazione Funzlone Hub Emofilia</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Malattie Emorragiche e Trombotiche Ospedale</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <zip>634-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>466-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ogikubo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>167-0035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University, School of Medicine, Seibu Hospital</name>
      <address>
        <city>Yokohama</city>
        <zip>241-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Blood Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perpetual Succour Hospital</name>
      <address>
        <city>Cebu</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemophilia Comprehensive Care Centre</name>
      <address>
        <city>Parktown</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. A Coruna</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 29, 2014</study_first_submitted>
  <study_first_submitted_qc>February 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

